These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18812025)

  • 1. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.
    Veng-Pedersen P; Freise KJ; Schmidt RL; Widness JA
    J Pharm Pharmacol; 2008 Oct; 60(10):1321-34. PubMed ID: 18812025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.
    El-Komy MH; Widness JA; Veng-Pedersen P
    Drug Metab Dispos; 2011 Apr; 39(4):603-9. PubMed ID: 21209249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.
    Reynaldo-Fernández G; Solozábal J; Amaro D; Fernández-Sánchez EM; Rodríguez-Vera L; Bermejo M; Mangas-Sanjuan V; Troconiz IF
    Eur J Pharm Sci; 2018 Jul; 120():123-132. PubMed ID: 29729414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.
    El-Komy MH; Schmidt RL; Widness JA; Veng-Pedersen P
    Biopharm Drug Dispos; 2011 Jul; 32(5):276-88. PubMed ID: 21678432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.
    Chapel SH; Veng-Pedersen P; Schmidt RL; Widness JA
    Exp Hematol; 2001 Apr; 29(4):425-31. PubMed ID: 11301182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic analysis of pegylated human erythropoietin in rats.
    Jolling K; Ruixo JJ; Hemeryck A; Piotrovskij V; Greway T
    J Pharm Sci; 2004 Dec; 93(12):3027-38. PubMed ID: 15503315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.
    Chanu P; Gieschke R; Charoin JE; Pannier A; Reigner B
    J Clin Pharmacol; 2010 May; 50(5):507-20. PubMed ID: 20179322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.
    Freise KJ; Widness JA; Segar JL; Schmidt RL; Veng-Pedersen P
    Pharm Res; 2007 Sep; 24(9):1653-9. PubMed ID: 17457660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
    Ait-Oudhia S; Scherrmann JM; Krzyzanski W
    J Pharmacol Exp Ther; 2010 Sep; 334(3):897-910. PubMed ID: 20501635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses.
    D'Cunha R; Widness JA; Yan X; Schmidt RL; Veng-Pedersen P; An G
    J Clin Pharmacol; 2019 Jun; 59(6):835-846. PubMed ID: 30618050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin.
    Xenocostas A; Cheung WK; Farrell F; Zakszewski C; Kelley M; Lutynski A; Crump M; Lipton JH; Kiss TL; Lau CY; Messner HA
    Eur J Clin Pharmacol; 2005 May; 61(3):189-95. PubMed ID: 15776276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans.
    Veng-Pedersen P; Widness JA; Pereira LM; Schmidt RL; Lowe LS
    Biopharm Drug Dispos; 1999 May; 20(4):217-23. PubMed ID: 10440797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.
    Jolling K; Perez Ruixo JJ; Hemeryck A; Vermeulen A; Greway T
    Eur J Pharm Sci; 2005 Apr; 24(5):465-75. PubMed ID: 15784336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in erythropoietin pharmacokinetics following hematopoietic transplantation.
    Widness JA; Schmidt RL; Hohl RJ; Goldman FD; Al-Huniti NH; Freise KJ; Veng-Pedersen P
    Clin Pharmacol Ther; 2007 Jun; 81(6):873-9. PubMed ID: 17429351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
    Macdougall IC; Robson R; Opatrna S; Liogier X; Pannier A; Jordan P; Dougherty FC; Reigner B
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1211-5. PubMed ID: 17699350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.
    Salmonson T; Danielson BG; Wikström B
    Br J Clin Pharmacol; 1990 Jun; 29(6):709-13. PubMed ID: 2378790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase.
    Aizawa K; Kawasaki R; Tashiro Y; Hirata M; Endo K; Shimonaka Y
    Int J Hematol; 2016 Aug; 104(2):182-9. PubMed ID: 27084258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin.
    Salmonson T
    Scand J Urol Nephrol Suppl; 1990; 129():1-66. PubMed ID: 2255869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens.
    D'Cunha R; Schmidt R; Widness JA; Mock DM; Yan X; Cress GA; Kuruvilla D; Veng-Pedersen P; An G
    Eur J Pharm Sci; 2019 Oct; 138():105013. PubMed ID: 31340188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
    Souillard A; Audran M; Bressolle F; Jaussaud P; Gareau R
    Biopharm Drug Dispos; 1996 Dec; 17(9):805-15. PubMed ID: 8968532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.